Verastem said clinical trials are evaluating VS-7375, its investigational KRAS G12D inhibitor, as a potential treatment option. The studies are testing the drug

Verastem said clinical trials are evaluating VS-7375, its investigational KRAS G12D inhibitor, as a potential treatment option. The studies are testing the drug both as a monotherapy and in combination, alongside a broader Q3 2026 pipeline update.